Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Vouchers For Pediatric Rare Disease: Will Popularity Force A Quick Halt?

Executive Summary

Based on designations, FDA already could have enough products in the pipeline to trigger the mandatory program stop and assessment.


Related Content

Priority Review Vouchers Could Be Used Frequently Next Year
Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain
Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice
For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher
BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval
FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Targeted Therapies On FDA’s Orphan Designation Radar
Pediatric Study Planning With FDA, EMA To Be More Closely Aligned
FDASIA Study Mandates Focus On Performance, But Could Slow Reviews
Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts